# Eupraxia (EPRX) — News

EPRX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/eprx/news

## Recent headlines

- [Eupraxia Pharmaceuticals Inc: Interim analysis of phase 2B portion of study is on track for December 2026](https://www.ainvest.com/news/eupraxia-pharmaceuticals-interim-analysis-phase-2b-portion-study-track-december-2026-2610) — AInvest Wire, Oct 15, 2026
- [Eupraxia Pharmaceuticals Inc: Resolve trial reaches enrollment target of 120 patients in phase 2B](https://www.ainvest.com/news/eupraxia-pharmaceuticals-resolve-trial-reaches-enrollment-target-120-patients-phase-2b-2610) — AInvest Wire, Oct 15, 2026
- [Fitch affirms Epif at 'BBB'; outlook stable](https://www.ainvest.com/news/fitch-affirms-epif-bbb-outlook-stable-2610) — AInvest Wire, Oct 14, 2026
  Fitch Ratings has affirmed its credit rating for Epif at 'BBB', with a stable outlook, reflecting the company's solid financial position and operational performance. The rating underscores Fitch's confidence in Epif's ability to maintain its creditworthiness amid evolving market conditions. The…
- [Epiroc AB: Barclays raises target price to SEK 285 from SEK 280](https://www.ainvest.com/news/epiroc-ab-barclays-raises-target-price-sek-285-sek-280-2610) — AInvest Wire, Oct 14, 2026
  Barclays has raised its target price for Epiroc AB (EPI.A) to SEK 285 from SEK 280, reflecting the firm’s confidence in the company’s operational performance and market positioning. The adjustment, while modest, underscores the analyst’s view of Epiroc’s strong fundamentals and continued growth in…
- [Eupraxia Pharmaceuticals - EP-104GI cohort 8B shows EoEhss stage -0.26 and grade -0.27 reduction at 36 weeks](https://www.ainvest.com/news/eupraxia-pharmaceuticals-ep-104gi-cohort-8b-shows-eoehss-stage-0-26-grade-0-27-reduction-36-weeks-2609) — AInvest Wire, Sep 30, 2026

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).